145 Percent Tariff Shock Spares Pharma for Now but Industry Faces Hidden Risks

Despite being exempted from the recent 10% baseline and steep tariff hikes imposed by the U.S., the pharmaceutical sector remains on edge. While the White House confirmed that drugs won’t immediately face the new trade measures, panic has already rippled through Asia-Pacific markets, underscoring how fragile global supply chains remain in this escalating economic confrontation.

Trump’s administration revealed two key reasons for the temporary exemption: to buy time for reshoring pharmaceutical manufacturing and to avoid potential drug price spikes or shortages. The message is clear—no tariff today doesn’t mean no impact tomorrow. President Trump himself issued a stark warning to pharma companies: either return to American soil or face massive levies later. “If they don’t come back,” he said, “they’ll pay a giant tax.”

The pharmaceutical industry now stands at a critical juncture. Multinational giants are left choosing between absorbing rising costs or relocating entire supply chains, both of which come with steep financial implications. The cost of raw materials, R&D investment, and logistics restructuring are all ballooning under tariff pressure.

Industry responses have been mixed. Germany’s Boehringer Ingelheim acknowledged the mounting risks, warning that tariffs on APIs, ingredients, or specialized equipment would erode Europe’s competitive edge. Meanwhile, Danish pharma titan Novo Nordisk kept silent on potential fallout but emphasized the need for “flexibility” in uncertain conditions.

In contrast, several Chinese pharma companies appeared unaffected—at least for now. BeiGene and Betta Pharmaceuticals noted that current tariffs primarily target goods-based trade, while licensing and IP-related exports remain outside the crosshairs. Moreover, China’s relatively small pharma export volume to the U.S. has so far shielded it from direct financial blowback.

However, the EU may be next in line, with Ireland seen as a likely target. In 2024 alone, the U.S. imported over €58 billion in pharmaceuticals and chemicals from Ireland. Given its favorable tax climate and vast production capacity, Ireland has become a tax-advantageous hub for drug giants like Pfizer and AbbVie—a fact unlikely to sit well with Trump’s trade team.

Belgium and Germany also risk tariff exposure. Belgium, home to Pfizer’s major European base, exported over $73 billion in drugs during the first 10 months of 2024—a quarter of which went to the U.S. With 15% of its total exports tied to pharmaceuticals, the stakes couldn’t be higher.

While China exports far less—$4.52 billion in active ingredients and $1.15 billion in formulations—the looming threat of policy change remains real. The U.S. Trade Representative’s April 3 list included dozens of medical products, indicating no sector is truly immune.

Looking ahead, the upcoming U.S. midterms could upend current tariff strategies altogether, leaving pharma investments hanging. What’s certain for now is that drugmakers, especially those reliant on exports, will likely shift R&D and focus more on innovation and patents as a hedge against future disruptions.